Novo Nordisk has come up short in…
Novo Nordisk has come up short in two phase 3 [...]
Novo Nordisk has come up short in two phase 3 [...]
VC Versant Ventures is unveiling Dayra Therapeutics, a new biotech [...]
A combination of Merck-partnered sac-TMT and Keytruda led to a [...]
Bayer’s oral FXIa inhibitor asundexian has significantly reduced the risk [...]
Los estudios sobre adultos que toman ISRS muestran que estos [...]
The 150-year-old drugmaker is the first company in health care [...]
Eli Lilly’s latest high-profile crossovers—which include a starry TV partnership [...]
Hundreds of industry leaders have signed a letter to FDA [...]
Maryland is becoming the home away from home for British [...]
The approval came “months earlier than anticipated,” Pfizer’s Chief Oncology Officer, [...]